Principles and applications of gene therapy in colon cancer

Journal of Gastrointestinal and Liver Diseases

Volumn 17, Issue 1, 2008, Pages 59-67

  Durai, Rajaraman ^a,b   Shi, Yu Yang ^a   Seifalian, Alexander M ^a,b   Winslet, Marc C ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Colon cancer; Gene; Gene therapy; Oncogene; Plasmid; Vectors

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ACICLOVIR; ADENOVIRUS VECTOR; ALKYLATING AGENT; CALCIUM PHOSPHATE; CARCINOEMBRYONIC ANTIGEN; CD3 ANTIGEN; CYTOSINE DEAMINASE; DIETHYLAMINOETHYLDEXTRAN; DOXIFLURIDINE; DRUG METABOLITE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GANCICLOVIR TRIPHOSPHATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMAGGLUTININ VIRUS VECTOR; HERPES SIMPLEX VIRUS VECTOR; INTERLEUKIN 2; LENTI VIRUS VECTOR; NITROREDUCTASE; ONCOFETAL ANTIGEN; PLASMID DNA; POX VIRUS VECTOR; RETROVIRUS VECTOR; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VIRUS VECTOR; VIRUS VECTOR;

CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; FAMILIAL CANCER; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSFER; HERPES SIMPLEX; HUMAN; LEUKEMIA; MELANOMA; MONOTHERAPY; MORBIDITY; NONHUMAN; POLYPOSIS; REVIEW; VIREMIA;

COLONIC NEOPLASMS; GENE THERAPY; HUMANS;

EID: 42449105771     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Boyle P, Langman JS. ABC of colorectal cancer: Epidemiology. BMJ 2000; 321: 805-808.
2. Midgley RS, Kerr DJ. ABC of colorectal cancer: adjuvant therapy. BMJ 2000; 321: 1208-1211.
3. Sabaawy HE, Farley T, Ahmed T, Feldman E, Abraham NG. Synergetic effects of retrovirus IFN-alpha gene transfer and 5-FU on apoptosis of colon cancer cells. Acta Haematol 1999; 101: 82-88.
4. Astrin SM. Are there molecular targets for therapy of colon cancer? Oncology (Williston Park) 1991; 5: 127-132.
5. Cornetta K, Wieder R, Anderson WF. Gene transfer into primates and prospects for gene therapy in humans. Prog Nucleic Acid Res Mol Biol 1989; 36: 311-322.
6. Anderson WF. Human gene therapy: scientific and ethical considerations. J Med Philos 1985; 10: 275-291.
7. Edelstein ML, Abedi MR, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide 1989-2004-an overview. J Gene Med 2004; 6: 597-602.
8. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006; 208: 299-318.
9. Wang Y, Hu JK, Krol A, Li YP, Li CY, Yuan F. Systemic dissemination of viral vectors during intratumoral injection. Mol Cancer Ther 2003; 2: 1233-1242.
10. Puck JM, Malech HL. Gene therapy for immune disorders: good news tempered by bad news. J Allergy Clin Immunol 2006; 117: 865-869.
11. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570-578.
12. Aebersold P, Kasid A, Rosenberg SA. Selection of gene-marked tumor infiltrating lymphocytes from post-treatment biopsies: a case study. Hum Gene Ther 1990; 1: 373-384.
13. Hiraoka K, Kimura T, Logg CR, et al. Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res 2007; 67: 5345-5353.
14. Zwacka RM, Dunlop MG. Gene therapy for colon cancer. Hematol Oncol Clin North Am 1998; 12: 595-615.
15. Li HJ, Everts M, Pereboeva L, et al. Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Cancer Res 2007; 67: 5354-5361.
16. Nakano K, Todo T, Zhao G, et al. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. J Gene Med 2005; 7: 638-648.
17. Maitra A. Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy. Expert Rev Mol Diagn 2005; 5: 893-905.
18. Cemazar M, Golzio M, Sersa G, Rols MP, Teissie J. Electrically-assisted nucleic acids delivery to tissues in vivo: where do we stand? Curr Pharm Des 2006; 12: 3817-3825.
19. Karmali PP, Chaudhuri A. Cationic liposomes as non-viral carriers of gene medicines: resolved issues, open questions, and future promises. Med Res Rev 2007; 27: 696-722.
20. Li S, Huang L. Nonviral gene therapy: promises and challenges. Gene Ther 2000; 7: 31-34.
21. Walther W, Stein U, Fichtner I, Schlag PM. Low-volume jet injection for efficient nonviral in vivo gene transfer. Mol Biotechnol 2004; 28: 121-128.
22. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-1266.
23. Takami K, Yana I, Kurahashi H, Nishisho I. Multistep carcinogenesis in colorectal cancers. Southeast Asian J Trop Med Public Health 1995; 26 Suppl 1: 190-196.
24. Cho KR, Vogelstein B. Genetic alterations in the adenoma-carcinoma sequence. Cancer 1992; 70: 1727-1731.
25. Samowitz WS, Slattery ML, Sweeney C, Herrick J, Wolff RK, Albertsen H. APC mutations and other genetic and epigenetic changes in colon cancer. Mol Cancer Res 2007; 5: 165-170.
26. Allen JI. Molecular biology of colon polyps and colon cancer. Semin Surg Oncol 1995; 11: 399-405.
27. Baba S. Recent advances in molecular genetics of colorectal cancer. World J Surg 1997; 21: 678-687.
28. Rahner N, Friedrichs N, Wehner M, et al. Nine novel pathogenic germline mutations in MLH1, MSH2, MSH6 and PMS2 in families with Lynch syndrome. Acta Oncol 2007; 46: 763-769.
29. Plotz G, Zeuzem S, Raedle J. DNA mismatch repair and Lynch syndrome. J Mol Histol 2006; 37: 271-283.
30. Kwak EL, Chung DC. Hereditary colorectal cancer syndromes: an overview. Clin Colorectal Cancer 2007; 6: 340-344.
31. Chen MJ, Chung-Faye GA, Searle PF, Young LS, Kerr DJ. Gene therapy for colorectal cancer: therapeutic potential. BioDrugs 2001; 15: 357-367.
32. Yamamoto H, Sekimoto M, Monden M. Future scope for gene therapy for liver metastasis of colon cancer. Nippon Geka Gakkai Zasshi 2001; 102: 412-416.
33. Huang JH, Wang Y, Li CH, Zhong DG, Lu HY. Experimental studies on the treatment of colon cancer by cytosine deaminase gene and 5-fluorocytosine. Zhonghua Zhong Liu Za Zhi 2005;27: 6-8.
34. Kerr DJ, Young LS, Searle PF, McNeish IA. Gene directed enzyme prodrug therapy for cancer. Adv Drug Deliv Rev 1997; 26: 173-184.
35. Meng RD, El Deiry WS. Tumor suppressor gene therapy for cancer: from the bench to the clinic. Drug Resist Updat 1998; 1: 205-210.
36. Walther W, Stein U, Fichtner I, et al. Nonviral jet-injection gene transfer for efficient in vivo cytosine deaminase suicide gene therapy of colon carcinoma. Mol Ther 2005; 12: 1176-1184.
37. Link CJ Jr., Levy JP, McCann LZ, Moorman DW. Gene therapy for colon cancer with the herpes simplex thymidine kinase gene. J Surg Oncol 1997; 64: 289-294.
38. Koyama F, Sawada H, Fujii H, et al. Enzyme/prodrug gene therapy for human colon cancer cells using adenovirus-mediated transfer of the Escherichia coli cytosine deaminase gene driven by a CAG promoter associated with 5-fluorocytosine administration. J Exp Clin Cancer Res 2000; 19: 75-80.
39. Gavelli A, Baque P, Mala M, et al. Vaccination by suicide gene therapy against a model of hepatic metastasis from colon cancer in the rat. Ann Chir 2000; 125: 552-559.
40. Kanyama H, Tomita N, Yamano T, et al. Enhancement of the antitumor effect of 5′-deoxy-5-fluorouridine by transfection of thymidine phosphorylase gene into human colon cancer cells. Jpn J Cancer Res 1999; 90: 454-459.
41. Chung-Faye G, Palmer D, Anderson D, et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 2001; 7: 2662-2668.
42. Chung-Faye GA, Kerr DJ, Young LS, Searle PF. Gene therapy strategies for colon cancer. Mol Med Today 2000; 6: 82-87.
43. Konson A, Ben-Kasus T, Mahajna JA, Danon A, Rimon G, Agbaria R. Herpes simplex virus thymidine kinase gene transduction enhances tumor growth rate and cyclooxygenase-2 expression in murine colon cancer cells. Cancer Gene Ther 2004; 11: 830-840.
44. Kagaya T, Nakamoto Y, Sakai Y, et al. Monocyte chemoattractant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer. Cancer Gene Ther 2006; 13: 357-366.
45. Koyama F, Sawada H, Hirao T, Fujii H, Hamada H, Nakano H. Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther 2000; 7: 1015-1022.
46. Hayashi S, Emi N, Yokoyama I, Namii Y, Uchida K, Takagi H. Inhibition of establishment of hepatic metastasis in mice by combination gene therapy using both herpes simplex virus-thymidine kinase and granulocyte macrophage-colony stimulating factor genes in murine colon cancer. Cancer Gene Ther 1997; 4: 339-344.
47. Nyati MK, Symon Z, Kievit E, et al. The potential of 5-fluorocytosine/ cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Ther 2002; 9: 844-849.
48. Hargest R. Current gene therapy strategies for colorectal cancer. Cancer Genomics 2000; 1: 103-115.
49. Linderholm B, Norberg T, Bergh J. Sequencing of the tumor suppressor gene TP 53. Methods Mol Med 2006; 120: 389-401.
50. Liu MC, Gelmann EP. P53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol 2002; 29: 246-257.
51. Chung-Faye GA, Kerr DJ. ABC of colorectal cancer: Innovative treatment for colon cancer. BMJ 2000; 321: 1397-1399.
52. Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996; 10: 2438-2451.
53. Dvory-Sobol H, Kazanov D, Arber N. Gene targeting approach to selectively kill colon cancer cells, with hyperactive K-Ras pathway. Biomed Pharmacother 2005; 59 Suppl 2: S370-S374.
54. Noda H, Kato Y, Yoshikawa H, et al. Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers. J Exp Clin Cancer Res 2006; 25: 235-242.
55. Bukholm IK, Nesland JM. Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch 2000; 436: 224-228.
56. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256: 102-105.
57. Keith FJ, Bradbury DA, Zhu YM, Russell NH. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 1995; 9: 131-138.
58. Aoki K, Ohnami S, Yoshida T. Suppression of pancreatic and colon cancer cells by antisense K-ras RNA expression vectors. Methods Mol Med 2005; 106: 193-204.
59. Rubin J, Galanis E, Pitot HC, et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther 1997; 4: 419-425.
60. Morse MA, Nair SK, Mosca PJ, et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003; 21: 341-349.
61. Alves A, Vibert E, Trajcevski S, et al. Adjuvant interleukin-12 gene therapy for the management of colorectal liver metastases. Cancer Gene Ther 2004; 11: 782-789.
62. Mazzolini G, Qian C, Xie X, et al. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther 1999; 6: 514-522.
63. Caruso M, Pham-Nguyen K, Kwong YL, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci U S A 1996; 93: 11302-11306.
64. Sun Y, Peng D, Lecanda J, et al. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Ther 2000; 7: 1467-1476.
65. Adris S, Chuluyan E, Bravo A, et al. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells. Cancer Res 2000; 60: 6696-6703.
66. Ueda K, Cornwell MM, Gottesman MM, et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986; 141: 956-962.
67. Hou S, Kou G, Fan X, Wang H, et al. Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU. Cancer Immunol Immunother 2007; 56: 1605-1613.
68. Yang B, Eshleman JR, Berger NA, Markowitz SD. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 1996; 2: 1649-1657.
69. Ogawa N, Fujiwara T, Kagawa S, et al. Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int J Cancer 1997; 73: 367-370.
70. Sabaawy HM, Ikehara S, Adachi Y, et al. Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-alpha gene transfer. Int J Oncol 1999; 14: 1143-1151.
71. Wildner O, Blaese RM, Candotti F. Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer. Cancer Res 1999; 59: 5233-5238.
72. Ishii M, Iwai M, Harada Y, et al. Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver. Cancer Lett 2007; 245: 134-143.
73. Adachi Y, Lee CT, Coffee K, et al. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 2002; 123: 1191-1204.
74. Uchida H, Shinoura N, Kitayama J, Watanabe T, Nagawa H, Hamada H. 5-Fluorouracil efficiently enhanced apoptosis induced by adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells. J Gene Med 2003; 5: 287-299.
75. Kobayashi T, Sawa H, Morikawa J, Zhang W, Shiku H. Bax induction activates apoptotic cascade via mitochondrial cytochrome c release and Bax overexpression enhances apoptosis induced by chemotherapeutic agents in DLD-1 colon cancer cells. Jpn J Cancer Res 2000; 91: 1264-1268.
76. Weiss MB, Vitolo MI, Baerenfaller K, Marra G, Park BH, Bachman KE. Persistent mismatch repair deficiency following targeted correction of hMLH1. Cancer Gene Ther 2007; 14: 98-104.
77. Zhang M, Li S, Li J, Ensminger WD, Lawrence TS. Ionizing radiation increases adenovirus uptake and improves transgene expression in intrahepatic colon cancer xenografts. Mol Ther 2003;8: 21-28.
78. Zamir G, Zeira E, Gelman AE, et al. Replication-deficient adenovirus induces host topoisomerase I activity: implications for adenovirus-mediated gene expression. Mol Ther 2007; 15: 772-781.
79. Zheng S, Xiao ZX, Pan YL, Han MY, Dong Q. Continuous release of interleukin 12 from microencapsulated engineered cells for colon cancer therapy. World J Gastroenterol 2003; 9: 951-955.
80. Reid T, Galanis E, Abbruzzese J, et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 2001; 8: 1618-1626.
81. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999; 59: 410-413.
82. Kievit E, Bershad E, Ng E, et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 1999; 59: 1417-1421.
83. Zhu H, Zhu Y, Hu J, et al. Adenovirus-mediated small hairpin RNA targeting Bcl-XL as therapy for colon cancer. Int J Cancer 2007; 121: 1366-1372.
84. Lan KL, Yen SH, Liu RS, Shih HL, Tseng FW, Lan KH. Mutant Bik gene transferred by cationic liposome inhibits peritoneal disseminated murine colon cancer. Clin Exp Metastasis 2007; 24: 461-470.
85. Kuwamura H, Tominaga K, Shiota M, et al. Growth inhibition of colon cancer cells by transfection of dominant-negative apoptosis signal-regulating kinase-1. Oncol Rep 2007; 17: 781-786.
86. Lemoine NR, McNeish IA. Gene transfer: Bax to the future for cancer therapy. Gut 2004; 53: 478-479.
87. Jie JZ, Wang JW, Qu JG, Hung T. Suppression of human colon tumor growth by adenoviral vector-mediated NK4 expression in an athymic mouse model. World J Gastroenterol 2007; 13: 1938-1946.
88. Wu X, Deng Y, Wang G, Tao K. Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells. J Surg Res 2007; 138: 56-63.
89. Durai R, Davies M, Yang W, et al. Biology of insulin-like growth factor binding protein-4 and its role in cancer (review). Int J Oncol 2006; 28: 1317-1325.
90. Durai R, Yang SY, Sales KM, Seifalian AM, Goldspink G, Winslet MC. Increased apoptosis and decreased proliferation of colorectal cancer cells using insulin-like growth factor binding protein-4 gene delivered locally by gene transfer. Colorectal Dis 2007; 9: 625-631.
91. Subramaniam V, Vincent IR, Gilakjan M, Jothy S. Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy. Exp Mol Pathol 2007; 83: 332-340.
92. Negroni L, Samson M, Guigonis JM, Rossi B, Pierrefite-Carle V, Baudoin C. Treatment of colon cancer cells using the cytosine deaminase/5-fluorocytosine suicide system induces apoptosis, modulation of the proteome, and Hsp90beta phosphorylation. Mol Cancer Ther 2007; 6: 2747-2756.
93. Hayashi S, Yokoyama I, Namii Y, Emi N, Uchida K, Takagi H. Inhibitory effect on the establishment of hepatic metastasis by transduction of the tissue plasminogen activator gene to murine colon cancer. Cancer Gene Ther 1999; 6: 380-384.
94. Vitale S, Cambien B, Karimdjee BF, et al. Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer. Gut 2007; 56: 365-372.
95. Iaitskii NA, Dubina MV, Vasil'ev SV, Popov DE, Krutovskikh VA. The scientific and clinical value of molecular genetic changes in the intercellular gap junctions observed in colon cancer. Vestn Ross Akad Med Nauk 2003; 24-29.
96. Ye YJ, Zhu XG, Wang S, Wang YC, Sang JL.Antisense to CDK4 inhibits the growth of human colon cancer cells HT29. Zhonghua Yi Xue Za Zhi 2006; 86: 846-849.
97. Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol 2001; 166: 1314-1319.
98. Jacob D, Bahra M, Schumacher G, Neuhaus P, Fang B. Gene therapy in colon cancer cells with a fiber-modified adenovector expressing the TRAIL gene driven by the hTERT promoter. Anticancer Res 2004; 24: 3075-3079.
99. Rychahou PG, Murillo CA, Evers BM. Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL). Surgery 2005; 138: 391-397.
100. Zhang L, Gu J, Lin T, Huang X, Roth JA, Fang B. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. Gene Ther 2002; 9: 1262-1270.
101. Mulkeen AL, Silva T, Yoo PS, et al. Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells. Arch Surg 2006; 141: 367-374.
102. Stoeltzing O, Ahmad SA, Liu W, et al. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 2003; 63: 3370-3377.
103. Dkhissi F, Lu H, Soria C, et al. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum Gene Ther 2003; 14: 997-1008.
104. Lukashev AN, Fuerer C, Chen MJ, Searle P, Iggo R. Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954. Hum Gene Ther 2005; 16: 1473-1483.